1. Academic Validation
  2. The conversion of formate into purines stimulates mTORC1 leading to CAD-dependent activation of pyrimidine synthesis

The conversion of formate into purines stimulates mTORC1 leading to CAD-dependent activation of pyrimidine synthesis

  • Cancer Metab. 2020 Sep 21;8:20. doi: 10.1186/s40170-020-00228-3.
Jacqueline Tait-Mulder 1 Kelly Hodge 1 David Sumpton 1 Sara Zanivan 1 2 Alexei Vazquez 1 2
Affiliations

Affiliations

  • 1 Cancer Research UK Beatson Institute, Switchback Road, Bearsden, Glasgow, G61 1BD UK.
  • 2 Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Abstract

Background: Mitochondrial serine catabolism to formate induces a metabolic switch to a hypermetabolic state with high rates of glycolysis, purine synthesis and pyrimidine synthesis. While formate is a purine precursor, it is not clear how formate induces pyrimidine synthesis.

Methods: Here we combine phospho-proteome and metabolic profiling to determine how formate induces pyrimidine synthesis.

Results: We discover that formate induces phosphorylation of carbamoyl phosphate synthetase (CAD), which is known to increase CAD enzymatic activity. Mechanistically, formate induces mechanistic target of rapamycin complex 1 (mTORC1) activity as quantified by phosphorylation of its targets S6, 4E-BP1, S6K1 and CAD. Treatment with the allosteric mTORC1 Inhibitor rapamycin abrogates CAD phosphorylation and pyrimidine synthesis induced by formate. Furthermore, we show that the formate-dependent induction of mTOR signalling and CAD phosphorylation is dependent on an increase in purine synthesis.

Conclusions: We conclude that formate activates mTORC1 and induces pyrimidine synthesis via the mTORC1-dependent phosphorylation of CAD.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-112066
    99.43%, SHMT1/2 Inhibitor